We are well into the fourth quarter with a number

We are well into the fourth quarter with a number of important milestones on the immediate horizon. JP gave us a nice cheat sheat, let's have a look at just part of that:

2b.) LymPro - incl. patients w/ mild AZ, enrollment 68 patient LP-002 exten. (est. 4Q14)
2c.) LymPro - incl. data announced from full cohort 140 subjects shortly thereafter
03.) LymPro - JV Partnership Agreement (est. 4Q14)
04.) LymPro - TBI / CTE update studies
05.) LymPro - Partner valid. of APP & CLIA cert. (est. 4Q14)

06.) Eltoprazine - 200 patient Ph. 2b trial PD-LID (est. 4Q14)
07.) Eltoprazine - US IND filed & apvd. for PD-LID (est. 4Q14)

08.) MANF - Ophthalmological ear toxicology complete data sets (est. 4Q14)
09.) MANF CVRO / CROA Glaucoma - animal data / IND to follow (completed 10/07/14)
10.) MANF / GDNF - Renishaw CED Ph. 2B test trial results (est. 4Q14)
11.) MANF RP - Orphan Drug (ODD) / 30 day FDA apvl. on 11/15 - (completed 10/16/14)
12.) MANF OIS - Ocular Ischemic Syndrome - ODD applic. filed (est. 4Q14)
13.) MANF DB-1 Wolframs - Retinal eye data test results (est. 4Q14)
14.) MANF DB-1 Wolframs - orphan potential (est. 4Q14)
15.) MANF - Good Mfg. Practices (GMP) for 1st in-man studies (est. 4Q14)

All that to say, we are today October 24--one more week in October, and BAM. Time is running out, with lost of important updates coming our way VERY SOON! Can't wait........Going be an exciting period of weeks coming up!